Asian Annals
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Amir J Khamooshi
Hossein Javadpour
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khamooshi, A. J
Right arrow Articles by Noohi, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khamooshi, A. J
Right arrow Articles by Noohi, F.
Asian Cardiovasc Thorac Ann 2007;15:493-496
© 2007 Asia Publishing EXchange Ltd


ORIGINAL CONTRIBUTIONS

Anticoagulation for Prosthetic Heart Valves in Pregnancy. Is There an Answer?

Amir J Khamooshi, MD, Fahimeh Kashfi, MScMW, Saeed Hoseini, MD, Mohammad B Tabatabaei, MD, Hossein Javadpour, FETCS, Fereydoon Noohi, MD

Department of Cardiac Surgery & Cardiology, Shahid Rajaee Heart Centre, Tehran, Iran

For reprint information contact: Hossein Javadpour, FETCS, Tel: 98 912 348 4368, Fax: 98 21 8809 5481, Email: javadpoursh{at}hotmail.com, Laleh General Hospital, Simay e Iran Avenue, Shahrak e Ghods, Tehran, Iran.

The aim of this retrospective study was to compare the different anticoagulation regimens used in pregnant women with prosthetic heart valves. We reviewed 196 pregnancies in 110 women from 1974 to 2000. The patients were divided into two groups: group 1 (142 pregnancies) had warfarin throughout pregnancy; and in group 2 (54 pregnancies), warfarin was replaced by subcutaneous heparin during the first trimester and last two weeks of pregnancy. There were no maternal complications in 129 pregnancies in group 1 and 44 in group 2. There were significantly fewer normal births in group 1 (56; 39.4%) compared to group 2 (39; 72.2%). Group 1 had a significantly higher rate of spontaneous abortion (46.5% vs 14.8%), but group 2 had a higher rate of valve thrombosis. In group 1, women with a warfarin requirement < 5 mg had a lower rate of spontaneous abortion. Warfarin is an effective anticoagulant in pregnant women with mechanical valves but it results in significant fetal loss when the dose is > 5 mg. Heparin is a less effective anticoagulant resulting in more maternal complications, but it is more protective of the fetus.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 by SAGE Publications